FOI 23/546

Dear

Thank you for your request of 16 July under the Freedom of Information Act. You requested:

> *Regarding products of Indian company. Patanjali Ayurved Ltd or Patanjali Foods Ltd or any company within the "Patanjali Group" or it's affiliates.(https://en.wikipedia.org/wiki/Patanjali_Ayurved) (herein "Patanjali"), I'm requesting since 2018 the following information:*
>
> 1. *Any information about product applications made by Patanjali or its affiliates to the MHRA*
> 2. *Any inspection related information of facilities of Patanjali or its affiliates*
> 3. *Any customer complaints received about Patanjali products on sale in the UK*
> 4. *Details of adverse sampling results/reports about Patanjali products that are found in any database/data of the MHRA*

Our responses to your four questions are included below:

1. Any information about product applications made by Patanjali or its affiliates to the MHRA

No information held.

2. Any inspection related information of facilities of Patanjali or its affiliates

No information held.

3. Any customer complaints received about Patanjali products on sale in the UK

We have a record of 1 referral for the product ‘Coronil Patanjali’ sold on amazon and on a specific website, this was removed from sale.

4. Details of adverse sampling results/reports about Patanjali products that are found in any database/data of the MHRA

In 2021 we were notified by Health Canada of an alert regarding Patanjali Dant Kanti Natural Power Toothpaste. That alert is available on the Health Canada website here: Patanjali Dant Kanti: Labelling issue - Canada.ca

The MHRA has not received any reports of suspected adverse drug reactions to Patanjali products. It important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different products. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular product, and may be stimulated by promotion and publicity about a drug.

Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time.

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk

Please remember to quote the reference number above in any future communications.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely
MHRA Customer Experience Centre
Communications and engagement team
Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU